[Botulinum toxin for the treatment of neurogenic detrusor hyperactivity. Consensus paper on use for neurogenic bladder dysfunction].
Due to elevated intravesical storage pressures, neurogenic bladder dysfunction carries a high risk of renal damage. Thus, the goals of neurourologic treatment are reduction of intravesical storage pressure and intermittent bladder emptying in order to protect renal function and to achieve continence. If anticholinergic medication is either ineffective or intolerable, several open and controlled studies showed that the injection of botulinum toxin A into the detrusor muscle is a minimally invasive, safe, and effective treatment option. These studies demonstrated an effective reduction of storage pressures and a significant increase in bladder capacity. The effect has been shown to last up to a year. As this treatment is not approved by European administrations, botulinum toxin A treatment fulfills all criteria for "justified off-label use." The reduction of intravesical storage pressure leads to an improvement of life expectancy due to upper urinary tract protection. Furthermore, quality of life can be improved by low incidence of urinary tract infections, secure continence, and physiologic catheterization intervals.
Sievert
K-D
KD
Klinik für Urologie, Universitätsklinikum, Hoppe-Seyler-Strasse 3, 72076, Tübingen, Deutschland. karl.sievert@med.uni-tuebingen.de
Bremer
J
J
Burgdörfer
H
H
Domurath
B
B
Hampel
C
C
Kutzenberger
J
J
Seif
C
C
Stöhrer
M
M
Wefer
B
B
Pannek
J
J
D019274:Botulinum Toxins, Type A / Q000627:therapeutic use*; D005858:Germany; D006801:Humans; D017410:Practice Guidelines as Topic; D010818:Practice Patterns, Physicians' / Q000592:standards*; D001750:Urinary Bladder, Neurogenic / Q000188:drug therapy* / Q000517:prevention & control*
D019274:Botulinum Toxins, Type A